Abstract 3096: Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients

2020 ◽  
Author(s):  
Carmen Rubio Alarcón ◽  
Dave E. van der Kruijssen ◽  
Lana Meiqari ◽  
Linda J. Bosch ◽  
John K. Simmons ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Prognostic Biomarker ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Tumor Dna

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer

JAMA Oncology ◽  
2020 ◽  
Vol 6 (6) ◽  
pp. 932
Author(s):  
Zhengyi Zhao ◽  
Shangli Cai ◽  
Zhijie Wang
Keyword(s):  
Colon Cancer ◽  
Prognostic Marker ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Tumor Dna

scholarly journals Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

JAMA Oncology ◽  
2019 ◽  
Vol 5 (12) ◽  
pp. 1710 ◽  
Author(s):  
Jeanne Tie ◽  
Joshua D. Cohen ◽  
Yuxuan Wang ◽  
Michael Christie ◽  
Koen Simons ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Recurrence Risk ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Dna Analyses ◽  
Risk And Benefit ◽  
Tumor Dna

ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Emre Yekedüz ◽  
Elif Berna Köksoy ◽  
Hakan Akbulut ◽  
Yüksel Ürün ◽  
Güngör Utkan
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Circulating Tumor Dna ◽  
Random Effects Model ◽  
Inverse Variance ◽  
Increased Risk ◽  
Significant Step ◽  
Tumor Dna

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on March 31, 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.

Intensity of adjuvant chemotherapy regimens and grade III–V toxicities among elderly stage III colon cancer patients

2016 ◽  
Vol 61 ◽  
pp. 1-10 ◽  
Author(s):  
F.N. van Erning ◽  
L.G.E.M. Razenberg ◽  
V.E.P.P. Lemmens ◽  
G.J. Creemers ◽  
J.F.M. Pruijt ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Grade Iii

Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients

Medical Care ◽  
2009 ◽  
Vol 47 (12) ◽  
pp. 1229-1236 ◽  
Author(s):  
Amy J. Davidoff ◽  
Thomas Rapp ◽  
Ebere Onukwugha ◽  
Ilene H. Zuckerman ◽  
Nader Hanna ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Stage Iii ◽  
Stage Iii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document